Moderate ResearchHealing & RecoveryLongevity

TB-500 (Ac-LKKTETQ)

TB-500

Thymosin Beta-4 Active Fragment | Healing Peptide

Half-life

Not precisely established; effects persist longer than 24 hours

Chain length

7 amino acids

Reference frequency

2x weekly (e.g., Monday and Thursday)

Research overview

DoseGear research brief

TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.

Mechanism of action

TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration. It promotes angiogenesis by upregulating VEGF expression and enhancing endothelial cell sprouting. The peptide undergoes serial cleavage at the C-terminus during metabolism, while the N-terminal acetylation provides protection from degradation.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Acetylated seven-amino-acid segment corresponding to thymosin-beta-4 residues 17–23.

What it is researched for

Experimental fragment activity and tissue-repair research involving proposed actin-associated cell migration.

Research observation window

Not reported for a validated human fragment study.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Injection site reactions
Mild fatigue
Head rush (reported)

Contraindications & cautions

Not authorized for medicinal use
Active cancer (theoretical concern)
Pregnancy or breastfeeding
Prohibited by WADA in sports

Scientific references

01
Synthesis and Characterization of N-terminal Acetylated 17-23 Fragment of Thymosin Beta-4
Scientific citationSynthesis and Characterization of N-terminal Acetylated 17-23 Fragment of Thymosin Beta-4. Drug Testing and Analysis (2012).
02
Doping Control Analysis of TB-500
Scientific citationDoping Control Analysis of TB-500. Journal of Chromatography B (2012).
03
TB-500 Metabolism and Wound Healing
Scientific citationTB-500 Metabolism and Wound Healing. Journal of Chromatography B (2024).
04
Investigation of TB-500 Metabolism
Scientific citationInvestigation of TB-500 Metabolism. WADA (2018).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity